Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration [0.03%]
乳腺癌免疫治疗反应的生物标志物预测：从单一标记到多组学整合
Ali Sanjari Moghaddam,Kit Y Lu,Elham Nasrollahi et al.
Ali Sanjari Moghaddam et al.
Immunotherapy has redefined treatment paradigms across several malignancies, yet its application in breast cancer remains limited to select subtypes, particularly triple-negative breast cancer. As immune checkpoint inhibitors advance into e...
HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis [0.03%]
HER2低表达和极低表达浸润性乳腺癌的临床病理特征及免疫组化一致性分析
Yu-Han Dong,Yi-Tong Xu,Xi-Zi Jiang et al.
Yu-Han Dong et al.
The DESTINY-Breast06 trial demonstrated survival benefits of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low/ultralow metastatic breast cancer. However, the associated clinicopathological features, HER2...
Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer [0.03%]
早期HER2阳性乳腺癌新辅助化疗的种族和民族差异
Inimfon Jackson,Xiudong Lei,Hui Zhao et al.
Inimfon Jackson et al.
We examined neoadjuvant chemotherapy (NACT) use, pathological complete response (pCR) and the association with overall survival (OS) among patients with early-stage HER2-positive breast cancer (BC). Patients ≥18 years with stage I-III HER2...
Personalized ctDNA detection and genomic profiling in the NeoRHEA Study [0.03%]
NeoRHEA研究中的个性化ctDNA检测和基因组分析
Alexandra Stanciu,Elisa Agostinetto,Andreas Papagiannis et al.
Alexandra Stanciu et al.
Circulating tumor DNA (ctDNA) is a promising biomarker in early hormone receptor (HR) + , HER2-negative breast cancer. We assessed ctDNA with the RaDaR assay in NeoRHEA (NCT03065621), a single-arm, phase II neoadjuvant palbociclib plus endo...
Night shift work and breast cancer: from etiopathology to precision risk analysis [0.03%]
从病因病理到精准风险评估：夜班工作与乳腺癌的关系
Silvia Vivarelli,Tania Formica,Ylenia Puliatti et al.
Silvia Vivarelli et al.
The increasing prevalence of night shift work (NSW) in our current professional landscape has raised significant public health concerns, particularly regarding its potential role in breast cancer (BC) development among women. Recognized by ...
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion [0.03%]
卡培斯韦替布治疗HR阳性/HER2阴性晚期乳腺癌临床监测和管理指南的优化：专家意见
Neil M Iyengar,Joyce A O&#x;Shaughnessy,Heather B Moore et al.
Neil M Iyengar et al.
Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer with ≥1 PIK3CA, AKT1, and/or PTEN alterations, significantly i...
Cancer cell-monocyte co-culture spheroids recapitulate pro-tumorigenic, immunosuppressive, and drug-resistant microenvironments in brain metastatic breast cancer [0.03%]
脑转移性乳腺癌细胞-单核细胞共培养球体模拟促肿瘤发生、免疫抑制和耐药的微环境
Sumiran Kumar Gurung,Kyra Berger,Shreyas S Rao
Sumiran Kumar Gurung
Monocyte derived macrophages (MDMs) comprise a major cellular fraction of the brain metastatic breast cancer (BMBC) tumor microenvironment (TME), however, their role in BMBC growth and response to therapeutics remains elusive. We developed ...
Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer [0.03%]
一项针对乳腺癌患者迟发型免疫毒性的机构间发生率和风险分析研究
Saya Jacob,Samantha Fisch,Carolyne Face et al.
Saya Jacob et al.
Immune checkpoint inhibitors (ICI) improve survival in triple-negative breast cancer (TNBC) but cause late-onset toxicity, with unknown incidence in breast cancer. This retrospective study included 700 patients (61%, n = 424 early-stage; 39...
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen [0.03%]
CDK2抑制可增强CDK4/6抑制剂在乳腺癌PDX模型中的抗肿瘤活性综合筛查结果
Nealia C House,Maxine M Chen,Sima Khazaei et al.
Nealia C House et al.
Aberrant cyclin-dependent kinase 2 (CDK2) activity is implicated as a resistance mechanism to CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Using prec...
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy [0.03%]
HER2低乳腺癌是免疫“冷”肿瘤：对肿瘤浸润性免疫细胞的见解及其对免疫治疗的影响
S Pizzamiglio,A Blanda,V Appierto et al.
S Pizzamiglio et al.
This study investigated, for the first time, the association between HER2 expression, immune infiltration inferred by CIBERSORTx, and immunotherapy response in HER2-negative early breast cancer (EBC). Gene expression was analyzed in prospec...